Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
|Formulation||Dosing Recommendations||Use in Pregnancy|
|Bictegravir/ Emtricitabine/ Tenofovir Alafenamide
Note: BIC is not available as a single-entity formulation.
||Standard Adult Dose:
||No data are available on placental transfer of BIC.
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
To maximize BIC absorption, doses should not be administered within 2 hours of ingestion of any preparation containing minerals such as iron or calcium, including prenatal vitamins.
|a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines, Appendix B, Table 8).
Key to Acronyms: ARV = antiretroviral; BIC = bictegravir; FTC = emtricitabine; FDC = fixed-dose combination; PK = pharmacokinetic; TAF = tenofovir alafenamide
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive